LivaNova wins FDA PMA for aura6000 sleep apnea device

CURRENT FULL VERSION: LivaNova has secured US FDA premarket approval for the aura6000 System, giving the company a new foothold in the obstructive sleep apnea market and expanding the field of implantable hypoglossal nerve stimulation therapies. FDA’s PMA database lists the decision date as March 18, 2026, and identifies the device as indicated for adult patients with moderate to severe obstructive sleep apnea, defined as an apnea-hypopnea index of 15 to 65, who have failed, don’t tolerate, or aren’t eligible for standard treatments including PAP, oral appliances, or pharmacotherapy. (accessdata.fda.gov)

The approval caps a multiyear regulatory path. LivaNova received FDA approval in June 2021 to start its investigational OSPREY study in the US, then reported in November 2024 that the randomized controlled trial had met its primary safety and efficacy endpoints. In May 2025, the company said it had completed its PMA submission and later released 12-month top-line data showing continued benefit. (investor.livanova.com)

What appears to distinguish aura6000 is both its stimulation strategy and its labeling position. LivaNova says the system uses proximal hypoglossal nerve stimulation with six electrodes placed on the proximal trunk of the hypoglossal nerve, allowing broader access to airway muscles and more customized titration through its PolySync algorithm. In its March 19, 2026 announcement, the company described aura6000 as the first and only hypoglossal nerve stimulation therapy approved in the US without complete concentric collapse contraindication or warning language. That stands out against FDA’s approved labeling for Inspire’s upper airway stimulation system, which still specifies that patients should not have complete blockage or concentric collapse of the soft palate. (markets.financialcontent.com)

The clinical data LivaNova has disclosed help explain the FDA win. In OSPREY, the company said the study achieved statistically significant primary endpoint responder rates versus sham control. At six months of therapy, assessed at the seven-month follow-up, the treatment arm showed a 66.2% reduction in median apnea-hypopnea index, from 34.3 to 11.6, and a 63.3% reduction in oxygen desaturation index, from 34.9 to 12.8. LivaNova also said there were no serious adverse device-related or procedure-related events through the primary endpoint visits. At 12 months, the company reported a 65% responder rate, plus 68% median reductions in both AHI and ODI. (investor.livanova.com)

Expert reaction in the public record is still fairly limited, but the company has highlighted comments from OSPREY lead investigator Dr. Atul Malhotra of UC San Diego, who said the early reductions in AHI and ODI showed a significant clinical impact for patients. LivaNova commercialization lead Lucile Blaise framed the approval as validation of an alternative for patients who are unsuccessful with PAP and said the company expects to bring its next-generation technology to market next year. Independent trade coverage has echoed that commercialization timeline, pointing to a planned first-half 2027 launch, pending FDA review of a supplement for the MRI-compatible version. (investor.livanova.com)

Why it matters: For veterinary professionals, this isn’t a direct animal health development, but it is still useful regulatory intelligence. It shows how FDA is evaluating implantable neurostimulation platforms with more nuanced patient-selection language, and how device makers are using randomized sham-controlled data to differentiate in a specialty market shaped by adherence problems with first-line therapy. It’s also a reminder that sleep apnea care is moving beyond a single-device paradigm in human medicine, which can influence investor attention, reimbursement policy, and cross-sector expectations for neuromodulation technologies more broadly. That broader point is reinforced by other recent FDA actions in neuromodulation, including breakthrough device designation for Nia Therapeutics’ Smart Neurostimulation System for episodic memory loss in adults with prior moderate to severe traumatic brain injury and persistent deficits. Nia’s system is described as a fully implantable, closed-loop platform that records neural activity from 60 channels across four brain regions and delivers targeted stimulation to the lateral temporal cortex; the company has cited a sham-controlled study in neurosurgical patients with epilepsy and prior TBI showing a 19% recall improvement, while random stimulation showed no benefit. (accessdata.fda.gov)

For industry watchers, the competitive angle matters too. Inspire already has an established FDA-approved system in the category, but aura6000 enters with a different stimulation approach and potentially broader eligibility language around complete concentric collapse. Whether that translates into faster uptake will depend less on the approval headline itself and more on surgeon training, payer policy, real-world outcomes, and post-approval evidence. At the same time, the wider neurostimulation field is still moving through earlier regulatory stages in adjacent indications: Nia has said it plans to file an IDE in 2026, a reminder that FDA’s support for implantable neuromodulation now spans both commercial-stage approvals and earlier breakthrough-designated programs. (markets.financialcontent.com)

What to watch: The next milestones are likely to be detailed FDA labeling documents and any summary of safety and effectiveness data, broader publication of OSPREY results, reimbursement decisions, and the FDA supplement review tied to LivaNova’s planned MRI-compatible launch in the first half of 2027. More broadly, neuromodulation watchers may also want to track whether Nia follows through on its planned 2026 IDE filing and whether its closed-loop memory-loss program continues to validate the FDA’s appetite for more targeted brain-stimulation systems. (accessdata.fda.gov)